-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx To Highlight NETs Plasma Biomarker In Precision Medicine At EHSF Malta Conference

Benzinga·02/04/2026 13:51:12
Listen to the news

 Showing New Indication for Nu.Q® NETs 

HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February. 

The session entitled "Empowering Precision‑medicine approach through NETs Plasma Biomarker‑driven personalized treatment"  will be presented by Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece.